Skip to content
  • About
    • What we do
    • Our history
    • Our team
    • Our committees
    • Our partners
    • About genomics
  • Services
    • What we offer
    • Research we’re supporting
  • Tools & resources
    • Search all tools & resources
    • Research ethics & governance
    • Consent & patient support materials
    • Evaluating genomic research & translation
    • Data governance
    • Access our datasets
    • Data capture & standardisation
    • Data analysis & interpretation
    • Workforce education
    • Our publications
    • Our submissions
  • Our project areas
    • Our project areas
    • Genomic information management
    • Clinical genomic practice
    • Genomic literacy, workforce & training
    • Indigenous genomic priorities
    • Genomic diagnostics
    • Evaluating genomic research & translation
    • Australian health system policy & practice
    • Involvement & engagement
  • News & events
    • News
    • Events
    • Personal stories
    • Search news & events
  • Connect with us

Whole-body MRI screening picks up early-stage cancers while still curable

Home All news & events News Whole-body MRI screening picks up early-stage…

An Australian and US research team, Dr Mandy Ballinger, Professor David Thomas (Garvan Institute of Medical Research), and Dr Ana Best and Dr Sharon Savage (National Cancer Institute, National Institutes of Health, USA) have shown conclusively that whole-body MRI detects primary cancers in people with an inherited cancer risk condition called Li-Fraumeni syndrome, at an early and curable stage, -at a rate of approximately one cancer per 10 individuals tested.

These findings are set to change clinical practice in monitoring those at high genetic risk of cancer and have been published today in leading cancer journal JAMA Oncology …continue reading at the Garvan Institute of Medical Research website.

Acknowledgement: Original article from the Garvan Institute of Medical Research.

Professor David Thomas (Director, Kinghorn Cancer Centre, Garvan Institute of Medical Research), leads the Australian Genomics cancer flagship, ‘Managing patient risk – AYA / PAED’. It aims to compare the genetic implications of patients recruited based on age-of-onset with family history, and to identify the spectrum of clinically actionable variants across a broad range of cancers, based on age of onset.


More news

Graphic of laptop with CTRL on the screen

Expanding research consent one ‘yes’ at a time

Australian Genomics has created a new version of its online platform CTRL (control) to enable...

June 30, 2022

Read More >

Couple with two young children, smiling at the baby on the mother's knee

Grants for Genomic Implementation Projects

Australian Genomics has funded eight new projects as part of its Genomic Implementation Projects grant...

May 30, 2022

Read More >

Mitochondrial cells

Mitochondrial donation now legal in Australia

The historic passing of the Mitochondrial Donation Law Reform (Maeve’s Law) Bill by the Australian...

March 31, 2022

Read More >


Connect with us

(03) 9936 6345
info@australiangenomics.org.au
50 Flemington Road, Parkville
Victoria 3052 Australia

In the spirit of reconciliation Australian Genomics acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

To stay informed about our work, sign up to our newsletter

Subscribe

Quicklinks

  • Home
  • What we do
  • What we offer
  • Tools & resources
  • Our publications
  • Our project areas
  • Research we’re supporting
  • Our team

Privacy

  • We follow the Australian Privacy Principles
  • General privacy policy
  • Website privacy policies
  • Terms & conditions

Website by Blueboat.